STTK logo

SHATTUCK LABS INC

STTKNASDAQ
🏆 #2885 by market capEarnings Nov 4US Equity
$526.47▼ $29.85 (−5.67%)
Simulated price
🔔
Track STTK
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$576M
Small Cap
📈Revenue Growth (YoY)
-82.5%
Declining
📊Gross Margin
-750.9%
Thin
💵FCF Margin
-4124.0%
Thin
⚖️P/S Ratio
575.7x
Expensive
Otter Score
44
Weak
No chart data available for STTK.

Trading Snapshot

Day Range
$523.29 – $529.25
52-Week Range
$1.70 – $8.33
Volume
$2.49B
Avg Volume
$2.72B
Shares Outstanding
90.4M
Next Earnings
Dec 10, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$227,341
P/E Ratio
-12.5
P/S Ratio
575.7x
EPS (TTM)
$-0.41
Dividend Yield
0.00%
Dilution (1yr)
+104.1%

Why Investors Own STTK

  • ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 39% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

STTK logo

SHATTUCK LABS INC

STTK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −82.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-195.1%▼ −1449.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$52M▼ −36.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$40M▼ −34.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
103.8M▲ +104.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$52M▼ −$2M YoY
StockOtter · stockotter.space

About SHATTUCK LABS INC

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$536.46
▲ +1.9% Upside
High Target$673.79
Low Target$416.43
Based on 21 analysts

Latest News & Updates

🚀
Reuters·2h ago

SHATTUCK LABS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift STTK price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

SHATTUCK LABS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.